

Genital Herpes (Infectious Disease) - Drugs In Development, 2021

<https://marketpublishers.com/r/G6D4C2D3AFA8EN.html>

Date: July 2021

Pages: 127

Price: US\$ 2,000.00 (Single User License)

ID: G6D4C2D3AFA8EN

Abstracts

Genital Herpes (Infectious Disease) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Genital Herpes - Drugs In Development, 2021, provides an overview of the Genital Herpes (Infectious Disease) pipeline landscape.

Genital herpes is a common sexually transmitted infection that affects both men and women. Genital herpes is caused by the herpes simplex virus (HSV). Symptoms include decreased appetite, fever, general sick feeling (malaise), muscle aches in the lower back, buttocks, thighs, or knees and swollen and tender lymph nodes in the groin during an outbreak. Treatment includes antiviral medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Genital Herpes - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Genital Herpes (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Genital Herpes (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Genital Herpes and features dormant and

discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 2, 25 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively.

Genital Herpes (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Genital Herpes (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Genital Herpes (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Genital Herpes (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Genital Herpes (Infectious Disease) therapeutics

based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Genital Herpes (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Genital Herpes (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Genital Herpes (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Genital Herpes - Overview

Genital Herpes - Therapeutics Development

Genital Herpes - Therapeutics Assessment

Genital Herpes - Companies Involved in Therapeutics Development

Genital Herpes - Drug Profiles

Genital Herpes - Dormant Projects

Genital Herpes - Discontinued Products

Genital Herpes - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Genital Herpes, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Genital Herpes - Pipeline by Abivax SA, 2021
Genital Herpes - Pipeline by AiCuris AG, 2021
Genital Herpes - Pipeline by AlphaVax Inc, 2021
Genital Herpes - Pipeline by Anteris Technologies Ltd, 2021
Genital Herpes - Pipeline by Astellas Pharma Inc, 2021
Genital Herpes - Pipeline by Auritec Pharmaceuticals Inc, 2021
Genital Herpes - Pipeline by Auro Vaccines LLC, 2021
Genital Herpes - Pipeline by Biomere LLC, 2021
Genital Herpes - Pipeline by BlueWillow Biologics Inc, 2021
Genital Herpes - Pipeline by Brandenburg Antiinfektiva GmbH, 2021
Genital Herpes - Pipeline by Innovative Molecules GmbH, 2021
Genital Herpes - Pipeline by iosBio Pharma Ltd, 2021
Genital Herpes - Pipeline by Johnson & Johnson, 2021
Genital Herpes - Pipeline by NanoViricides Inc, 2021
Genital Herpes - Pipeline by Rational Vaccines Inc, 2021
Genital Herpes - Pipeline by Redbiotec AG, 2021
Genital Herpes - Pipeline by Sanofi, 2021
Genital Herpes - Pipeline by Shulov Innovative Science Ltd, 2021
Genital Herpes - Pipeline by SL VaxiGen Inc, 2021
Genital Herpes - Pipeline by Starpharma Holdings Ltd, 2021
Genital Herpes - Pipeline by Stealth Biologics LLC, 2021
Genital Herpes - Pipeline by Thyreos LLC, 2021
Genital Herpes - Pipeline by United BioPharma Inc, 2021

Genital Herpes - Pipeline by Vaccibody AS, 2021
Genital Herpes - Pipeline by Vaxart Inc, 2021
Genital Herpes - Pipeline by Vaxxit Srl, 2021
Genital Herpes - Pipeline by Vir Biotechnology Inc, 2021
Genital Herpes - Pipeline by Viramatix Sdn Bhd, 2021
Genital Herpes - Pipeline by Vironova Medical AB, 2021
Genital Herpes - Dormant Projects, 2021
Genital Herpes - Dormant Projects, 2021 (Contd..1)
Genital Herpes - Dormant Projects, 2021 (Contd..2)
Genital Herpes - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Genital Herpes, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

I would like to order

Product name: Genital Herpes (Infectious Disease) - Drugs In Development, 2021

Product link: <https://marketpublishers.com/r/G6D4C2D3AFA8EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G6D4C2D3AFA8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970